Published online before print October 9, 2008

This Article Full Text Full Text (PDF) Supplemental Material All Versions of this Article: ajpath.2008.080308v1 173/5/1551    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Provenzano, P. P. Articles by Keely, P. J. Search for Related Content PubMed PubMed Citation Articles by Provenzano, P. P. Articles by Keely, P. J.

(American Journal of Pathology. 2008;173:1551-1565.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.080308

Mammary Epithelial-Specific Disruption of Focal Adhesion Kinase Retards Tumor Formation and Metastasis in a Transgenic Mouse Model of Human Breast Cancer

Paolo P. Provenzano^*, David R. Inman^*, Kevin W. Eliceiri, Hilary E. Beggs^¶ and Patricia J. Keely^*

From the Departments of Pharmacology,^* and Biomedical Engineering, the Laboratory for Optical and Computational Instrumentation, and the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, Wisconsin; and the Departments of Ophthalmology and Physiology,^¶ University of California, San Francisco, California

Focal adhesion kinase (FAK) is a central regulator of the focal adhesion, influencing cell proliferation, survival, and migration. Despite evidence demonstrating FAK overexpression in human cancer, its role in tumor initiation and progression is not well understood. Using Cre/LoxP technology to specifically knockout FAK in the mammary epithelium, we showed that FAK is not required for tumor initiation but is required for tumor progression. The mechanistic underpinnings of these results suggested that FAK regulates clinically relevant gene signatures and multiple signaling complexes associated with tumor progression and metastasis, such as Src, ERK, and p130Cas. Furthermore, a systems-level analysis identified FAK as a major regulator of the tumor transcriptome, influencing genes associated with adhesion and growth factor signaling pathways, and their cross talk. Additionally, FAK was shown to down-regulate the expression of clinically relevant proliferation- and metastasis-associated gene signatures, as well as an enriched group of genes associated with the G₂ and G₂/M phases of the cell cycle. Computational analysis of transcription factor-binding sites within ontology-enriched or clustered gene sets suggested that the differentially expressed proliferation- and metastasis-associated genes in FAK-null cells were regulated through a common set of transcription factors, including p53. Therefore, FAK acts as a primary node in the activated signaling network in transformed motile cells and is a prime candidate for novel therapeutic interventions to treat aggressive human breast cancers.